SecurityCFI / Culp, Inc.
IndustryBroadwoven Fabric Mills, Cotton
Institutional Buyers38
Opened Positions2
Related CULP / Culp, Inc.

Institutional and Fund Ownership - Buyers

Major holders that have opened new positions in CFI / Culp, Inc. include Nisa Investment Advisors L.l.c., and Great West Life Assurance Co /can/.

This page shows changes in the ownership structure by listing institutions, funds, and major shareholders that have increased their holdings or opened new positions in the last reporting period. Green rows indicate new positions. Click the link icon to see the full transaction history.

File DateFormInvestor Prev Shares Shares Change
(Percent)
Prev Value
(x$1000)
Current Value (x$1000) Change
(Percent)
2018‑05‑11 13F-HR Russell Investments Group, Ltd. 3,450 4,257 23.39 112 130 16.07
2017‑02‑10 13F-HR BlackRock Fund Advisors 294,292 340,246 15.62 8,761 12,640 44.28
2018‑05‑15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 76,006 78,564 3.37 2,546 2,400 -5.73
2018‑05‑01 13F-HR WEDGE CAPITAL MANAGEMENT L L P/NC 18,600 21,949 18.01 623 671 7.70
2018‑05‑15 13F-HR Invesco Ltd. 12,527 15,335 22.42 420 468 11.43
2018‑05‑04 13F-HR VICTORY CAPITAL MANAGEMENT INC 1,133,450 1,261,345 11.28 37,971 38,534 1.48
2018‑04‑19 13F-HR Endurance Wealth Management, Inc. 0 100 0 3
2018‑05‑08 13F-HR US BANCORP \DE\ 1,824 1,871 2.58 61 57 -6.56
2018‑05‑10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 134 4
2018‑04‑04 13F-HR CONFLUENCE INVESTMENT MANAGEMENT LLC 132,492 139,357 5.18 4,439 4,258 -4.08
2018‑05‑15 13F-HR QS Investors, LLC 2,217 2,406 8.53 74 74 0.00
2018‑05‑14 13F-HR Renaissance Technologies LLC 620,200 625,100 0.79 20,777 19,097 -8.09
2018‑05‑09 13F-HR EAGLE ASSET MANAGEMENT INC 136,209 156,112 14.61 4,563 4,769 4.51
2018‑04‑23 13F-HR Advisory Services Network, LLC 0 1,109 0 34
2018‑05‑10 13F-HR THOMSON HORSTMANN & BRYANT INC 213,430 216,649 1.51 7,149 6,618 -7.43
2018‑05‑16 13F-HR Foundry Partners, LLC 46,695 47,195 1.07 1,564 1,442 -7.80
2018‑04‑23 13F-HR FIRST TRUST ADVISORS LP 9,355 10,033 7.25 313 307 -1.92
2018‑05‑11 13F-HR BNP PARIBAS ARBITRAGE, SA 2,325 2,343 0.77 77,888 71,579 -8.10
2018‑05‑15 13F-HR BARCLAYS PLC 1,941 2,398 23.54 65 74 13.85
2017‑02‑10 13F-HR BlackRock Institutional Trust Company, N.A. 583,665 598,606 2.56 17,376 22,238 27.98
2018‑05‑15 13F-HR KEYBANK NATIONAL ASSOCIATION/OH 25,375 25,950 2.27 850 793 -6.71
2018‑05‑11 13F-HR DIMENSIONAL FUND ADVISORS LP 733,426 734,910 0.20 24,569 22,452 -8.62
2018‑05‑15 13F-HR STATE STREET CORP 194,490 202,264 4.00 6,519 6,181 -5.18
2018‑05‑11 13F-HR ISTHMUS PARTNERS, LLC 24,646 26,120 5.98 826 798 -3.39
2018‑05‑15 13F-HR Bank of New York Mellon Corp 91,159 92,672 1.66 3,054 2,831 -7.30
2018‑05‑14 13F-HR RAYMOND JAMES & ASSOCIATES 8,528 8,607 0.93 286 263 -8.04
2018‑05‑15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 0 200 0 6
2018‑04‑10 13F-HR NISA INVESTMENT ADVISORS L.L.C. 275 8
2018‑05‑15 13F-HR PANAGORA ASSET MANAGEMENT INC 28,488 36,338 27.56 954 1,110 16.35
2018‑05‑15 13F-HR JOHNSON INVESTMENT COUNSEL INC 23,000 26,120 13.57 770 797 3.51
2018‑05‑15 13F-HR UBS Group AG 107,999 114,039 5.59 3,618 3,484 -3.70
2018‑05‑15 13F-HR BANK OF AMERICA CORP /DE/ 59,180 64,485 8.96 1,983 1,969 -0.71
2018‑05‑15 13F-HR Keeley-Teton Advisors, LLC 38,110 56,277 47.67 1,277 1,719 34.61
2018‑05‑14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 26,634 26,971 1.27 892 824 -7.62
2018‑05‑18 13F-HR/A ROYAL BANK OF CANADA 52,433 54,786 4.49 1,756 1,674 -4.67
2018‑04‑26 13F-HR SIMPLEX TRADING, LLC 101 176 74.26 3 5 66.67
2017‑08‑10 13F-HR ABERDEEN ASSET MANAGEMENT PLC/UK 1,273,928 1,367,922 7.38 39,747 44,458 11.85
2018‑05‑14 13F-HR ALLIANCEBERNSTEIN L.P. 6,000 6,700 11.67 201 205 1.99

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 230215105